A Phase I Study of G3139 Subcutaneous in Solid Tumors

Completed · Phase 1

Conditions studied: Tumors

In brief

Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or central intravenous line. The route of administration limits the convenience of treatment, and catheter-related complications have been reported. This study is designed to evaluate the pharmacokinetics and safety of G3139 administered by subcutaneuous injection.

Key facts

Study ID
NCT00543231
Run by
Genta Incorporated
People needed
8
Starts
2005-12-01
Expected to finish
2006-12-01
Last updated by the study team
2007-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.